BiotechTube

zetomipzomib + placebo + zetomipzomib in open-label extension

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Hepatitis

Conditions

Autoimmune Hepatitis

Trial Timeline

May 23, 2023 → Apr 30, 2025

NCT ID
NCT05569759

About zetomipzomib + placebo + zetomipzomib in open-label extension

zetomipzomib + placebo + zetomipzomib in open-label extension is a phase 2 stage product being developed by Kezar Life Sciences for Autoimmune Hepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05569759. Target conditions include Autoimmune Hepatitis.

What happened to similar drugs?

0 of 13 similar drugs in Autoimmune Hepatitis were approved

Approved (0) Terminated (3) Active (10)
🔄SatralizumabChugai PharmaceuticalPhase 3
🔄Enteric-coated Mycophenolate SodiumNovartisPhase 3
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
🔄rilzabrutinib + placeboSanofiPhase 3
❌parsaclisinib + placeboIncytePhase 3
❌Intravenous Immunoglobulin + Placebos + Normal SalineGrifolsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05569759Phase 2Completed

Competing Products

20 competing products in Autoimmune Hepatitis

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
47
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
Enteric-coated Mycophenolate SodiumNovartisPhase 3
40
Ianalumab + PlaceboNovartisPhase 3
44
VAY736NovartisPhase 2/3
38
remibrutinibNovartisPhase 1
29
RO7049665RochePhase 2
27
rituximab (Mabthera®) + PlaceboRochePhase 3
40
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
42
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
35
BMS-986165Bristol Myers SquibbPhase 1
29
NivolumabBristol Myers SquibbPhase 1
21
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
36
BMS-986165 + RosuvastatinBristol Myers SquibbPhase 1
29
SAR445088SanofiPhase 1
21
BIVV020SanofiPhase 1
29
rilzabrutinibSanofiPhase 2
39